ArticlePLoS neglected tropical diseases2019
Antifungal activity of two oxadiazole compounds for the paracoccidioidomycosis treatment.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Synthesis, molecular docking and biological activity assessment of novel 1,3,4-oxadiazole derivatives as broad-spectrum antifungal candidates.RSC advances · 2026Article
- Paracoccidioidomycosis in the 21st century: Challenges and milestones.PLoS neglected tropical diseases · 2026Review
- Synthesis and antimicrobial evaluation of hybrids methoxynaphthalene-Future medicinal chemistry · 2025Article
- Design, Synthesis and Biological Activity Evaluation of β-Carboline Derivatives Containing Nitrogen Heterocycles.Molecules (Basel, Switzerland) · 2024Article
- Efficient selective targeting ofRSC medicinal chemistry · 2022Article
- Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative AgainstPathogens (Basel, Switzerland) · 2021Article
- One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021Review
- Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model.Frontiers in cellular and infection microbiology · 2021Article
- Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?Journal of fungi (Basel, Switzerland) · 2020Review
- Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type.Molecules (Basel, Switzerland) · 2020Article
- Article
- Two New 1,3,4-Oxadiazoles With Effective Antifungal Activity AgainstFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paracoccidioidomycosis (PCM) is a neglected disease present in Latin America with difficulty in treatment and occurrence of serious sequelae. Thus, the development of alternative therapies is imperative. In the current work, two oxadiazole compounds (LMM5 and LMM11) presented fungicidal activity against Paracoccidioides spp. The minimum inhibitory and fungicidal concentration values ranged from 1 to 32 μg/mL, and a synergic effect was observed for both compounds when combined with Amphotericin B. LMM5 and LMM11 were able to reduce CFU counts (≥2 log10) on the 5th and 7th days of time-kill curve, respectively. The fungicide effect was confirmed by fluorescence microscopy (FUN-1/FUN-2). The hippocratic screening and biochemical analysis were performed in Balb/c male mice that received a high dose of each compound, and the compounds showed no in vivo toxicity. The treatment of experimental PCM with the new oxadiazoles led to significant reduction in CFU (≥1 log10). Histopathological analysis of the groups treated exhibited control of inflammation, as well as preserved lung areas. These findings suggest that LMM5 and LMM11 are promising hits structures, opening the door for implementing new PCM therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.